Tovaxin News

A board to discuss future MS therapies in early stage (Phase I or II) trials.

Tovaxin News

Postby NHE » Sun Aug 28, 2005 4:35 am

David McWilliams, CEO of PharmaFrontiers Corp, recently gave an interview with StreetIQ.com on August 25, 2005. The mp3 audio file of the interview can be found here. While the interview is targeted towards investors and not a scientific audience, there is still some very encouraging news none-the-less. During the interview, David McWilliams indicates that they are obtaining a 90% reduction in relapses! In addition, he states that 40% of their patients have improved physically with an improvement in disability scores ranging from 0.5 to 3 points on a 10 point scale within 6 months, and that the treatment is "stopping the progression of the disease!" 8O

NHE
User avatar
NHE
Volunteer Moderator
 
Posts: 3331
Joined: Sat Nov 20, 2004 4:00 pm

Advertisement

Postby Arron » Sun Aug 28, 2005 11:27 am

excellent research and news! thanks for sharing :)
Disclaimer: Any information you find on this site should not be considered medical advice. All decisions should be made with the consent of your doctor, otherwise you are at your own risk.
User avatar
Arron
Volunteer Moderator
 
Posts: 892
Joined: Sun Feb 01, 2004 4:00 pm
Location: California, USA


Return to Drug Pipeline

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service